- Home
- BSET vs VERU Comparison
BSET vs VERU Comparison
Compare BSET & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSET
- VERU
- Stock Information
- Founded
- BSET 1902
- VERU 1971
- Country
- BSET United States
- VERU United States
- Employees
- BSET N/A
- VERU N/A
- Industry
- BSET Home Furnishings
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- BSET Consumer Discretionary
- VERU Health Care
- Exchange
- BSET Nasdaq
- VERU Nasdaq
- Market Cap
- BSET 122.8M
- VERU 108.8M
- IPO Year
- BSET 1987
- VERU 1990
- Fundamental
- Price
- BSET $15.13
- VERU $0.57
- Analyst Decision
- BSET
- VERU Strong Buy
- Analyst Count
- BSET 0
- VERU 4
- Target Price
- BSET N/A
- VERU $4.00
- AVG Volume (30 Days)
- BSET 20.8K
- VERU 6.2M
- Earning Date
- BSET 04-02-2025
- VERU 02-13-2025
- Dividend Yield
- BSET 5.29%
- VERU N/A
- EPS Growth
- BSET N/A
- VERU N/A
- EPS
- BSET N/A
- VERU N/A
- Revenue
- BSET $329,923,000.00
- VERU $16,886,419.00
- Revenue This Year
- BSET $3.74
- VERU N/A
- Revenue Next Year
- BSET $4.09
- VERU N/A
- P/E Ratio
- BSET N/A
- VERU N/A
- Revenue Growth
- BSET N/A
- VERU 22.46
- 52 Week Low
- BSET $12.11
- VERU $0.49
- 52 Week High
- BSET $15.96
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- BSET 60.43
- VERU 44.48
- Support Level
- BSET $13.82
- VERU $0.49
- Resistance Level
- BSET $15.53
- VERU $0.56
- Average True Range (ATR)
- BSET 0.58
- VERU 0.05
- MACD
- BSET 0.14
- VERU 0.00
- Stochastic Oscillator
- BSET 77.27
- VERU 63.62
About BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.